NCT05494541

Characteristics of Patients With Sickle Cell Disease

Characteristics of Patients With Sickle Cell Disease Who Initiate Crizanlizumab Therapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 540 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 16 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This was a retrospective descriptive analysis of health care claims data using the IQVIA open source medical and pharmacy claims databases.

Detailed description

Patients with a diagnosis of SCD between November 1, 2018 and April 30, 2021 were identified. Among these patients, those who initiated crizanlizumab between November 1, 2019 and January 31, 2021 (index period) were selected into the treatment cohort. The indexing timeframe allowed for a 1-year lookback period and a minimum of 3 months (3m cohort) of follow-up. A subset of the 3m cohort with 6-months of available (6m cohort) follow-up was performed. The index date was the date of the first crizanlizumab administration. Study period: 01 November 2018 - 30 April 2021 Index period: 01 November 2019 - 31 January 2021 Index date: Date of the first claim for administration of crizanlizumab in the index period

Conditions

• Sickle Cell Disease

Interventions

Type	Name	Description
OTHER	Crizanlizumab	Patients who initiated crizanlizumab between November 1, 2019 and January 31, 2021 (index period) were selected into the treatment cohort.

Timeline

• Start date: 2021-08-30
• Primary completion: 2021-10-27
• Completion: 2021-10-27
• First posted: 2022-08-10
• Last updated: 2022-11-08

Locations

1 site across 1 country: United States